The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech company, stressed that point with TheStreet Pro’s Chris ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Unexpected delays, infighting and a staffing crisis are fueling investors’ unease.

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

A Pfizer-backed biotech landed $120M, embattled Kala Bio has secured a new CEO, and Akebia Therapeutics bought a rare kidney ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation ...